Our ambition to discover and develop new medicines of high therapeutic value has a solid basis: At seven research sites about 6,400 people working in R&D drive our projects successfully 'from mind to humankind'.
The R&D strategy is directed towards seven major therapeutic areas: cardiovascular diseases, central nervous system (CNS) diseases, immunology/inflammation, metabolic diseases, oncology, respiratory diseases and virology.
Continuous initiatives to increase research productivity result in a well-balanced pipeline showing a substantial number of innovative new molecular entities (NMEs) and a high share of products in late phase development.
Boehringer Ingelheim's successes in Research & Development continously strengthen its portfolio of future medications and offer true therapeutic benefit for patients.
